Mesoblast Ltd Sponsored ADR
Mesoblast Ltd Sponsored ADR is a biotechnology company focused on developing regenerative medicine products and allogeneic, off-the-shelf cellular therapies. The company’s platform is built around mesenchymal lineage cell technology designed for use across severe inflammatory and immune-mediated conditions, as well as selected cardiovascular and spine-related disorders. Its current pipeline includes cell-based medicines intended for hospital and specialist care settings, reflecting a focus on complex diseases with limited treatment options. Mesoblast operates through research, development, and commercialization activities across multiple regions, including Australia, the United States, Singapore, and Switzerland. As an ADR, Mesoblast Ltd Sponsored ADR gives U.S. investors access to the company’s underlying ordinary shares while representing a global healthcare business centered on advanced cell therapy and regenerative medicine.
$13.28
-$0.67 (-4.80%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-363.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 191.4% YoY with margins expanding 619.2pp.
Negative free cash flow of -$51M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$17M
▲ +191.4% YoY
Net Income (TTM)
-$102M
▼ -16.1% YoY
Op. Margin
-363.08%
▲ +619.2pp YoY
ROIC
-7.45%
Cash Flow & Balance Sheet
FCF (TTM)
-$51M
▼ -3.9% YoY
Op. Cash Flow (TTM)
-$50M
▼ -38.0% YoY
Net Debt
-$33M
Net Cash Position
Cash & Equiv.
$161M
3Y CAGR: +19.0%
Continue Research
Is Mesoblast Ltd Sponsored ADR (MESO) overvalued?
Mesoblast Ltd Sponsored ADR (MESO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Mesoblast Ltd Sponsored ADR scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Mesoblast Ltd Sponsored ADR a high-quality business?+
Mesoblast Ltd Sponsored ADR scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -363.1% operating margin and a -7.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Mesoblast Ltd Sponsored ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh MESO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.